$30 Billion Deal, page-4948

Especially as Viraleze did............

Starpharma’s Viraleze antiviral nasal spray has passed another trial confirming its effectiveness – this time showing it provides protection against infection with the highly transmissible SARS-CoV-2 Omicron variant of the virus which causes Covid-19.

One hundred per cent of animals treated with Viraleze in a viral challenge test by Scripps Research had no detectable virus in the lung, trachea or nasal cavity at up to four days after the trial.

Viraleze was effective if administered before and after exposure to the virus. Further animals treated with the nasal spray only after exposure to the virus exhibited greater than 99.999 percent reduction in viral load at day seven.